EUVIMEDEUVIMED entdecken
Open Access

Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals

Sarah E Smith-Jeffcoat iD, Jessica E Biddle iD, H Keipp Talbot iD, Kerry Grace Morrissey iD, Melissa S Stockwell iD, Yvonne Maldonado iD, Huong Q McLean iD, Katherine D Ellingson iD, Natalie M Bowman iD, Edwin Asturias iD, Alexandra M Mellis iD, Sheroi Johnson iD und 25 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Sarah E Smith-Jeffcoat und 36 weiteren Autor:innen. Beteiligte Einrichtung: Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Ritonavir, Viral Load, SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: RVTN, CDC HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nirmatrelvir/ritonavir (N/R) reduces severe outcomes from coronavirus disease 2019 (COVID-19); however, rebound after treatment has been reported. We compared symptom and viral dynamics in individuals with COVID-19 who completed N/R treatment and similar untreated individuals.

Methods

We identified symptomatic participants who tested severe acute respiratory syndrome coronavirus 2–positive and were N/R eligible from a COVID-19 household transmission study. Index cases from ambulatory settings and their households contacts were enrolled. We collected daily symptoms, medication use, and respiratory specimens for quantitative polymerase chain reaction for 10 days during March 2022—May 2023. Participants who completed N/R treatment (treated) were propensity score matched to untreated participants. We compared symptom rebound, viral load (VL) rebound, average daily symptoms, and average daily VL by treatment status measured after N/R treatment completion or 7 days after symptom onset if untreated.

Results

Treated (n = 130) and untreated participants (n = 241) had similar baseline characteristics. After treatment completion, treated participants had greater occurrence of symptom rebound (32% vs 20%; P = .009) and VL rebound (27% vs 7%; P < .001). Average daily symptoms were lower among treated participants without symptom rebound (1.0 vs 1.6; P < .01) but not statistically lower with symptom rebound (3.0 vs 3.4; P = .5). Treated participants had lower average daily VLs without VL rebound (0.9 vs 2.6; P < .01) but not statistically lower with VL rebound (4.8 vs 5.1; P = .7).

Conclusions

Individuals who completed N/R treatment experienced fewer symptoms and lower VL but rebound occured more often compared with untreated individuals. Providers should prescribe N/R, when indicated, and communicate rebound risk to patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirViral LoadSARS-CoV-2COVID-19OutpatientsCOVID-19 Drug TreatmentPropensity ScoreHumansMaleFemaleAdultMiddle AgedAntiviral AgentsAged

Stichwörter der Autor:innen

SARS-CoV-2antiviral treatmentreboundsymptomsviral loads

Substanzen

RitonavirAntiviral Agents

Autor:innen und Institutionen

  • Coronavirus and Other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Westat, Rockville, Maryland, USA.
  • Division of Child and Adolescent Health, Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
  • Department of Population and Family Health, Columbia University Mailman School of Public Health, New York, New York, USA.

ORCID-Profile: Sarah E Smith-Jeffcoat, Jessica E Biddle, H Keipp Talbot, Kerry Grace Morrissey, Melissa S Stockwell, Yvonne Maldonado, Huong Q McLean, Katherine D Ellingson, Natalie M Bowman, Edwin Asturias, Alexandra M Mellis, Sheroi Johnson, Hannah L Kirking, Melissa A R Rolfes, Lori Merrill, Steph Battan-Wraith, Ellen Sano, Son H McLaren, Clea C Sarnquist, Joshua G Petrie, Edward A Belongia, Karen Lutrick, Suchitra Rao, Phillip P Salvatore

Förderung

  • RVTN
  • CDC HHS
  • NIAID NIH HHS
  • Vanderbilt University Medical Center
  • Intramural CDC HHS
  • Trustees of Columbia University
  • CDC

Zitieren

APA

Smith-Jeffcoat, S. E., Biddle, J. E., Talbot, H. K., Morrissey, K. G., Stockwell, M. S., Maldonado, Y., McLean, H. Q., Ellingson, K. D., Bowman, N. M., Asturias, E., Mellis, A. M., Johnson, S., Kirking, H. L., Rolfes, M. A. R., Olivo, V., Merrill, L., Battan-Wraith, S., Sano, E., McLaren, S. H., …, & Salvatore, P. P. (2024). Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad696

Vancouver

Smith-Jeffcoat SE, Biddle JE, Talbot HK, Morrissey KG, Stockwell MS, Maldonado Y, et al. Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad696

BibTeX
@article{SmithJeffcoat2024,
  author = {Smith-Jeffcoat, Sarah E and Biddle, Jessica E and Talbot, H Keipp and Morrissey, Kerry Grace and Stockwell, Melissa S and Maldonado, Yvonne and McLean, Huong Q and Ellingson, Katherine D and Bowman, Natalie M and Asturias, Edwin and Mellis, Alexandra M and Johnson, Sheroi and Kirking, Hannah L and Rolfes, Melissa A R and Olivo, Vanessa and Merrill, Lori and Battan-Wraith, Steph and Sano, Ellen and McLaren, Son H and Vargas, Celibell Y and Goodman, Sara and Sarnquist, Clea C and Govindaranjan, Prasanthi and Petrie, Joshua G and Belongia, Edward A and Ledezma, Karla and Pryor, Kathleen and Lutrick, Karen and Bullock, Ayla and Yang, Amy and Haehnel, Quenla and Rao, Suchitra and Zhu, Yuwei and Schmitz, Jonathan and Hart, Kimberly and Grijalva, Carlos G and Salvatore, Phillip P},
  title = {Symptoms, Viral Loads, and Rebound Among COVID-19 Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score–Matched Untreated Individuals},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad696}
}
Kostenlos starten →